Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
Serotonin receptor ligandpsilocin, psilocybin, LSD +3 morepsilocin, psilocybin, LSD, DMT, mescaline, DOI show less
4-HO-EPT
4-hydroxy-N-ethyl-N-propyltryptamine
4-HO-EPT (4-hydroxy-N-ethyl-N-propyltryptamine) — also known as Eprocin — is a synthetic psychedelic of the tryptamine class. It is a structural analog of psilocin, the active compound in psilocybin mushrooms, but with larger side chains that reduce its binding strength at the core serotonin target.[1] It activates serotonin receptors in the brain, producing the visual and cognitive shifts characteristic of classical psychedelics.[2]
4-HO-EPT (4-hydroxy-N-ethyl-N-propyltryptamine) — also known as Eprocin — is an emerging synthetic psychedelic of the tryptamine class. It is a structural analog of psilocin, distinguished by bulkier nitrogen substituents that weaken its primary psychedelic binding.[1] 4-HO-EPT is a 5-HT₂A receptor agonist, producing its effects by disrupting default sensory filtering with concurrent 5-HT₁A sedative modulation.[2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
Serotonin receptor ligandpsilocin, psilocybin, LSD +3 morepsilocin, psilocybin, LSD, DMT, mescaline, DOI show less
4-HO-EPT appeared on research chemical markets around 2016, a relatively obscure tryptamine even within that niche.[3] The first peer-reviewed study — a metabolic characterization that found its breakdown products in a postmortem blood sample — was published in 2024.[4] As of 2026, it remains unscheduled in most jurisdictions and circulates in small quantities among research chemical users.
Subjective effects include geometric visual patterns, emotional warmth, mood elevation, sedation, and transpersonal states. The experience is gentler and more body-oriented than psilocin — a sedative warmth and anxiolytic quality run through it, less visually sharp than comparable tryptamines.[2] Nausea, anxiety during onset, and bodily heaviness are common unwanted effects.
4-HO-EPT produces no physical dependence, and the lethal dose in humans is unknown.[5] The primary acute risk is psychological distress scaling with dose; a theoretical long-term concern comes from strong binding to a receptor associated with heart valve damage from sustained daily use.[1] The entire evidence base is one peer-reviewed paper, no clinical trials, and no toxicology data — this is a poorly understood substance.[4]
History[edit]
Discovery
The origins of 4-HO-EPT are poorly documented. Web sources attribute its synthesis to Alexander Shulgin in 1967, but this cannot be verified — the parent compound EPT is absent from TiHKAL, the 1997 book documenting 55 tryptamines Shulgin personally investigated.[3] Whether Shulgin synthesized it without publishing, or the attribution is simply wrong, remains an open question. citation needed
Research Chemical Market
4-HO-EPT appeared on research chemical vendor listings around 2016. It is available as a hemifumarate salt from specialist suppliers including Cayman Chemical.[6] The related compound 4-AcO-EPT has been confirmed by X-ray crystallography,[7] establishing that the EPT tryptamine series can be produced to research-grade purity.
First Peer-Reviewed Study
The first and only peer-reviewed study of 4-HO-EPT was published in 2024. Bergh et al. mapped its metabolic pathways using human liver tissue and identified unique metabolites in a postmortem blood sample from a suspected intoxication case.[4] This remains the only published research directly investigating 4-HO-EPT as of 2026.
The name Eprocin follows the informal naming pattern of the 4-hydroxytryptamine series — psilocin (4-HO-DMT), metocin (4-HO-MET), miprocin (4-HO-MiPT) — where the suffix reflects the N-alkyl substituents. EPT itself is described as "rarely encountered" in forensic literature, first identified in products seized in Japan.[3]
Chemistry[edit]
Structural Class
4-HO-EPT belongs to the 4-hydroxytryptamine family of substituted tryptamines — the same chemical class as psilocin and 4-HO-MET. Its molecular formula is C₁₅H₂₂N₂O (246.35 g/mol). The closely related compound 4-AcO-EPT is a presumed prodrug: it converts to 4-HO-EPT in the body, mirroring how psilocybin converts to psilocin.[1]
Structure-Activity Relationships
The defining structural feature is asymmetric nitrogen substitution: one ethyl group and one propyl group, larger than psilocin's two methyl groups. Larger N-alkyl groups reduce binding to the primary psychedelic receptor,[8] explaining the higher dose requirement compared to psilocin.
Adding the 4-hydroxyl group to the parent compound EPT substantially increases receptor affinity.[9] It is supplied commercially as a hemifumarate salt,[6] and the crystal structure of the related 4-AcO-EPT has been confirmed by X-ray analysis.[7]
Pharmacology[edit]
Mechanism of Action
4-HO-EPT activates serotonin receptors in the brain, disrupting normal sensory filtering and producing the visual and cognitive shifts of classical psychedelics.[2][10] This is confirmed by the standard animal behavioral test for hallucinogenic activity.[6] It also activates a second serotonin receptor type associated with calming and anxiety relief,[2] which accounts for the sedative warmth distinguishing it from more stimulating tryptamines.
Its strongest binding is to a third receptor type linked to heart valve damage when activated daily over months to years.[1] This is the same mechanism responsible for cardiac adverse effects seen with certain older weight-loss drugs. Whether the intermittent use typical of psychedelics carries any meaningful risk through this pathway has not been studied.
Pharmacokinetics
No human pharmacokinetic data exist. Community estimates place onset at 30–60 minutes, peak at 1–2 hours, and total duration at 3–7 hours.safety citation needed Lab analysis and a postmortem case have mapped its breakdown products, though real-world metabolism differs from lab predictions.[4][11] Primary breakdown likely proceeds through the enzyme MAO-A.[12]
Neuroscience[edit]
Where It Acts
No brain imaging studies have been conducted with 4-HO-EPT. As a serotonin receptor activator, it is expected to act on neurons in the prefrontal cortex, increasing brain activity and disrupting the default mental filters that normally constrain perception.[13] Its concurrent activation of calming serotonin receptors may dampen this destabilizing effect,[2] potentially explaining why the experience feels more manageable than psilocin at comparable intensity.
Why It Matters
The leading theory of psychedelic action holds that serotonin receptor activation weakens top-down mental filtering, allowing more raw sensory information into awareness.[13] For 4-HO-EPT, the proportionally stronger calming receptor engagement may produce a less extreme state than psilocin at equivalent potency. Whether it promotes brain rewiring — as demonstrated for psilocin — has not been tested.
- Does 4-HO-EPT's strong binding at the heart-valve-linked receptor produce measurable cardiovascular effects distinct from other 4-hydroxytryptamines?
- Does the weaker psychedelic receptor affinity produce a qualitatively different experience, or merely a dose-shifted version of the same thing?
- Does 4-HO-EPT promote brain rewiring, and does the calming receptor activity change the magnitude or timing of any such effect?
Subjective Effects[edit]
4-HO-EPT produces a classical psychedelic experience — visual distortion, emotional deepening, and transpersonal states — but with a distinctive warmth running through it at all doses. A sedative, anxiolytic quality shapes the whole experience. It feels grounded in the body, less cognitively sharp than many tryptamines.
Compared to psilocin, 4-HO-EPT requires higher doses to reach equivalent intensity and delivers a less visually dominant, more somatically textured experience.[1] Duration is broadly similar. These comparisons rest on community reports and receptor pharmacology — no controlled head-to-head studies exist.
4-HO-EPT appeared on research chemical markets around 2016; the parent compound EPT is described as "rarely encountered" in forensic literature.[3] The first peer-reviewed study directly addressing 4-HO-EPT — a metabolic characterization including a human postmortem blood case — was published in 2024.[4] It remains unscheduled in most jurisdictions and circulates in small quantities among research chemical users.
Subjective effects include geometric visual distortion, cognitive intensification, emotional enhancement, and transpersonal experience. The experience is described as a gentler, more body-oriented tryptamine psychedelic — sedative warmth and anxiolytic undertones from 5-HT₁A co-agonism distinguish it from the sharper visual dominance of psilocin.[2] Nausea, anxiety during onset, and bodily heaviness are common unsought effects.
4-HO-EPT produces no physical dependence, and the lethal dose is unknown — rapid tolerance after a single dose makes compulsive redosing self-limiting.[5] The primary acute risk is psychological distress scaling with dose and predisposition; a theoretical chronic concern arises from strong serotonin₂B receptor binding, a target linked to heart valve damage with sustained exposure.[1] Almost nothing is known from controlled study — one peer-reviewed paper, no clinical trials, and no toxicology data constitute the entire evidence base.[4]
History[edit]
Discovery
The origins of 4-HO-EPT are poorly documented. Multiple web sources attribute synthesis to Alexander Shulgin in 1967, but this claim is unverifiable: the parent compound EPT is absent from TiHKAL (1997), which documents 55 tryptamines Shulgin personally investigated.[3] Whether Shulgin synthesized 4-HO-EPT without publishing the work, or whether the attribution is spurious, remains an open question. citation needed
Research Chemical Market
4-HO-EPT appeared on research chemical vendor listings around 2016, marketed as a novel psychoactive substance. It is commercially available as the hemifumarate salt from specialist suppliers including Cayman Chemical.[6] The closely related prodrug 4-AcO-EPT has been characterized by X-ray crystallography,[7] confirming that academic-grade synthesis of the EPT tryptamine series is well established.
First Peer-Reviewed Study
The first peer-reviewed publication addressing 4-HO-EPT appeared in 2024, when Bergh et al. characterized its metabolic profile using human liver microsomes and identified unique metabolites in a human postmortem blood sample from a suspected intoxication case.[4] This study remains the only published work directly investigating 4-HO-EPT as of 2026.
The name Eprocin follows the informal naming convention used across the 4-hydroxytryptamine series — psilocin (4-HO-DMT), metocin (4-HO-MET), miprocin (4-HO-MiPT) — where the suffix derives from the N-alkyl substituents. EPT itself is described as "rarely encountered" in forensic literature, first identified in illicit products seized in Japan.[3]
Chemistry[edit]
Structural Class
4-HO-EPT belongs to the 4-hydroxytryptamine subclass of substituted tryptamines — indoleamine compounds with a hydroxyl group at the 4-position of the indole ring. This substitution pattern is shared with psilocin (4-HO-DMT) and 4-HO-MET (4-HO-MET). The distinguishing feature of 4-HO-EPT is its asymmetric nitrogen substitution: one ethyl and one propyl group, in contrast to psilocin's symmetric dimethyl pattern.
The closely related 4-acetoxy form (4-AcO-EPT) functions as a presumed prodrug — the acetyl group undergoes hydrolysis in vivo to yield 4-HO-EPT, paralleling the psilocybin-to-psilocin conversion established across the class.[1]
Molecular Properties
| Molecular formula | C₁₅H₂₂N₂O |
| Molecular weight | 246.35 g/mol |
The molecular structure comprises an indole ring system with a 4-hydroxyl substituent and a 2-aminoethyl side chain terminating in an N-ethyl-N-propyl tertiary amine. The indole NH remains unsubstituted.
Stereochemistry
4-HO-EPT contains no chirality centers and exists as a single achiral species. The asymmetric N-alkyl substitution introduces constitutional asymmetry but not stereoisomerism.
Structure-Activity Relationships
Across the 4-hydroxytryptamine series, increasing the size of N-alkyl substituents preferentially reduces 5-HT₂A receptor affinity.[8] 4-HO-EPT's ethyl-propyl combination represents a larger substitution than psilocin's dimethyl, consistent with its weaker psychedelic binding and higher dose requirements. Addition of the 4-hydroxyl group to the parent compound EPT substantially increases 5-HT₂A affinity, as established across the tryptamine class.[9]
Physical Properties
No published characterization of melting point, solubility, or stability exists for 4-HO-EPT. The hemifumarate salt is supplied commercially as a solid.[6] The crystal structure of the closely related 4-AcO-EPT fumarate salt has been determined,[7] but equivalent data for 4-HO-EPT are not available. As a 4-hydroxytryptamine, the compound is expected to degrade under aerobic conditions, consistent with the known oxidative instability of psilocin.
Pharmacology[edit]
Mechanism of Action
4-HO-EPT acts as an agonist at multiple serotonin receptor subtypes. Its psychedelic effects are driven by activation of the 5-HT₂A receptor, the established target for hallucinogenic activity across the tryptamine class.[2][10] The compound induces the head-twitch response in mice, a behavioral marker that directly confirms hallucinogenic potential.[6]
Meaningful co-agonism at the 5-HT₁A receptor is present. Activation of 5-HT₁A attenuates psychedelic intensity and contributes anxiolytic and sedative qualities, as characterized for the structurally related compound psilocin.[2]
The compound's strongest binding target is the 5-HT₂B receptor.[1] Chronic activation of this receptor is an established mechanism of heart valve damage for drugs taken daily over months to years (fenfluramine, certain ergot derivatives), though the implications for intermittent psychedelic use are unstudied.
The parent compound EPT has been described as a partial agonist at 5-HT₂A.[11] Addition of the 4-hydroxyl group substantially increases 5-HT₂A affinity relative to the unsubstituted parent, as established across the tryptamine class.[8][9]
Pharmacokinetics
No published human pharmacokinetic data exist for 4-HO-EPT. Community-derived estimates place onset at 30–60 minutes, peak at 1–2 hours, and total duration at 3–7 hours by the oral route; these values have not been confirmed by controlled study.safety citation needed
Metabolic pathways have been characterized in vitro using human liver microsomes and in vivo from a postmortem case.[4] The primary in vitro pathway involves double bond formation, accompanied by N-dealkylation and hydroxylation. The in vivo metabolic pattern diverges, with hydroxylation predominating — consistent with discrepancies observed for the parent compound EPT in animal models.[11]
By structural analogy to psilocin, oral absorption is expected to be rapid, and primary metabolism is inferred to proceed via MAO-A (MAO-A).[12] Specific enzyme involvement for 4-HO-EPT has not been determined.
Neuroscience[edit]
Where It Acts
No direct neuroimaging or electrophysiology studies have been conducted with 4-HO-EPT. As a serotonin 2A receptor agonist, it is expected to act on layer V pyramidal neurons in the prefrontal cortex, increasing glutamate transmission, disrupting default mode network integrity, and raising cortical entropy — the established neural signature of serotonergic psychedelics.[13]
Its concurrent 5-HT₁A activity may dampen this cortical destabilization through inhibitory receptors in raphe nuclei and limbic regions, potentially accounting for reports of a more manageable subjective character compared to psilocin at comparable intensity.[2]
Why It Matters
The REBUS model (relaxed beliefs under psychedelics) provides the dominant theoretical framework: 5-HT₂A agonism increases cortical entropy, weakens top-down predictive filtering, and allows sensory information to reach consciousness with less constraint.[13] For 4-HO-EPT, the proportionally greater 5-HT₁A engagement may produce a less entropic state than psilocin at equivalent receptor occupancy.
Whether the compound promotes structural neuroplasticity — as demonstrated for psilocin and other 5-HT₂A agonists — has not been tested.
- Does 4-HO-EPT's strong serotonin₂B binding produce measurable cardiovascular or subjective effects distinct from other 4-hydroxytryptamines?
- Does the weaker 5-HT₂A affinity produce a qualitatively different psychedelic experience, or merely a dose-shifted version of the same phenomenology?
- Does 4-HO-EPT promote neuroplasticity through the psychoplastogen pathway, and does 5-HT₁A co-activity modulate the magnitude or timecourse of structural plasticity?
Subjective Effects[edit]
4-HO-EPT produces a classical tryptamine psychedelic experience — visual distortion, cognitive and emotional deepening, and transpersonal states — but its pharmacological signature lends a distinct character. The proportionally stronger 5-HT₁A engagement introduces a sedative, anxiolytic undertone that tempers the experience relative to more 5-HT₂A-selective tryptamines. Set and setting exert significant influence across all dose ranges; no controlled subjective-effects studies have been conducted.
Compared to psilocin, 4-HO-EPT requires higher doses to reach equivalent intensity and may produce a less visually dominant, more somatically textured experience.[1] Duration is broadly comparable. These comparisons derive from community reports and receptor pharmacology — no head-to-head studies exist.
Effect Grid
Common doses produce a full psychedelic state with clear visual distortions — color enhancement, visual drifting, pattern recognition enhancement, and geometric patterning. Cognitive effects include conceptual thinking, thought connectivity, and meaningful introspective engagement. Emotional intensification is pronounced, with both positive and challenging emotional content amplified.
Physically, a sustained body high is present alongside spontaneous body sensations, mild muscle tension, and occasional yawning. Nausea during the come-up is more likely than at light doses. The 5-HT₁A co-agonism may contribute a more grounded, less anxious character compared to psilocin at equivalent psychedelic intensity.
Functional impairment is significant — driving, complex tasks, and professional obligations are not compatible. Duration is typically 4–6 hours with possible residual effects for several hours afterward.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Color enhancement · Visual breathing · Tracers · Brightness alteration · Environmental patterning · Holotropic state · Depth perception distortion · Perspective distortion · After-images · Symmetrical texture repetition · Auditory enhancement · Light sensitivity · Peripheral vision distortion · Sound sensitivity · Spatial disorientation · Touch enhancement · Visual haze / noise · Visual morphing · Visual acuity enhancement · Visual diffraction · Auditory distortion · Auditory misinterpretation · Dreaming enhancement · Ganzfeld effect · Peripheral misidentification · Proprioceptive distortion · Vestibular distortion · Visual melting · Synesthesia · Visual magnification · Visual processing acceleration · Visual acuity suppression · Olfactory enhancement · Taste enhancement · Flashbacks · Object transformations · Internal hallucinations · Environmental orbism / cubism · External hallucinations · Object activation · Visual recursion · Auditory hallucinations · Perspective hallucinations · Visual flipping · Visual processing suppression · Persisting hallucinations
Environmental patterning · Holotropic state · Depth perception distortion · Perspective distortion · After-images · Symmetrical texture repetition · Auditory enhancement · Light sensitivity · Peripheral vision distortion · Sound sensitivity · Spatial disorientation · Touch enhancement · Visual haze / noise · Visual morphing · Visual acuity enhancement · Visual diffraction · Auditory distortion · Auditory misinterpretation · Dreaming enhancement · Ganzfeld effect · Peripheral misidentification · Proprioceptive distortion · Vestibular distortion · Visual melting · Synesthesia · Visual magnification · Visual processing acceleration · Visual acuity suppression · Olfactory enhancement · Taste enhancement · Flashbacks · Object transformations · Internal hallucinations · Environmental orbism / cubism · External hallucinations · Object activation · Visual recursion · Auditory hallucinations · Perspective hallucinations · Visual flipping · Visual processing suppression · Persisting hallucinations
Appetite suppression · Physical fatigue · Stimulation · Tactile euphoria · Tingling / electric sensations · Vibrations / buzzing · Wakefulness · Nausea · Bodily heaviness · Bodily lightness · Bodily pressures · Dizziness · Heart rate perception changes · Insomnia · Laughter fits · Muscle tension · Restlessness · Body schema distortion · Dehydration sensation · Dry mouth · Excessive sweating · Muscle relaxation · Sedation · Sexual arousal enhancement · Yawning · Abnormal heartbeat · Breathing alteration · Bruxism · Headache · Involuntary body movements · Nystagmus (eye wobbles) · Respiratory stimulation · Salivation · Trembling · Vasoconstriction · Watery eyes · Vomiting · Bodily dissociation · Tactile hallucination
Tactile euphoria · Tingling / electric sensations · Vibrations / buzzing · Wakefulness · Nausea · Bodily heaviness · Bodily lightness · Bodily pressures · Dizziness · Heart rate perception changes · Insomnia · Laughter fits · Muscle tension · Restlessness · Body schema distortion · Dehydration sensation · Dry mouth · Excessive sweating · Muscle relaxation · Sedation · Sexual arousal enhancement · Yawning · Breathing alteration · Bruxism · Headache · Involuntary body movements · Nystagmus (eye wobbles) · Respiratory stimulation · Salivation · Trembling · Vasoconstriction · Watery eyes · Vomiting · Bodily dissociation · Tactile hallucination
Conceptual thinking · Cognitive euphoria · Immersion enhancement · Cognitive flexibility · Introspection enhancement · Openness enhancement · Thought connectivity · Cognitive impairment · Increased nature relatedness · Multiple thought streams · Creativity enhancement · Memory suppression · Thought loops · Analysis enhancement · Cognitive fatigue · Confusion · Focus suppression · Humor enhancement · Memory fragmentation · Motivation suppression · Synchronicity · Thought acceleration · Thought disorganization · Information processing enhancement · Information processing suppression · Memory replays · Focus enhancement · Motivation enhancement · Analysis suppression · Cognitive dysphoria · Delusions of sobriety · Language suppression · Thought deceleration · Compulsive redosing urge · Delusions · Amnesia
Cognitive flexibility · Introspection enhancement · Openness enhancement · Thought connectivity · Cognitive impairment · Increased nature relatedness · Multiple thought streams · Creativity enhancement · Memory suppression · Thought loops · Analysis enhancement · Cognitive fatigue · Confusion · Focus suppression · Humor enhancement · Memory fragmentation · Motivation suppression · Synchronicity · Thought acceleration · Thought disorganization · Information processing enhancement · Information processing suppression · Memory replays · Focus enhancement · Motivation enhancement · Analysis suppression · Cognitive dysphoria · Language suppression · Thought deceleration · Compulsive redosing urge · Delusions · Amnesia
Empathy enhancement · Simultaneous emotions · Anxiety · Catharsis · Anxiety suppression · Dysphoria · Irritability
Anxiety suppression · Dysphoria · Irritability
Sociability enhancement · Social connection · Trust enhancement · Flow state · Communication enhancement · Automaticity · Communication suppression · Compulsive behavior reduction · Sociability suppression · Social disconnection · Ego inflation · Boundary dissolution · Craving · Cognitive disconnection · Ego dissolution · Identity alteration · Telepathic feelings
Communication enhancement · Automaticity · Communication suppression · Compulsive behavior reduction · Sociability suppression · Social disconnection · Ego inflation · Boundary dissolution · Craving · Cognitive disconnection · Ego dissolution · Identity alteration · Telepathic feelings
Time cessation
Entity contact · Transpersonal memory access · Transpersonal visions · Cessation · Death-rebirth sequence · Voidness · Near-death experience
Death-rebirth sequence · Voidness · Near-death experience
Mindfulness enhancement · Recursive awareness
Timeline
First awareness of altered state; mild body sensations and subtle anticipatory mood shift. Effects are sub-threshold — a sense that something has changed without clear perceptual distortion.
Progressive intensification of body and perceptual effects. Nausea is most likely during this phase. Color brightening and initial visual breathing may emerge alongside building emotional sensitivity.
Maximum psychedelic intensity with visual, cognitive, emotional, and transpersonal effects at full expression. Visual drifting, geometry, and color enhancement are most pronounced. Introspective depth and emotional amplification peak here.
Gradual reduction in intensity. Visual effects diminish before cognitive effects. Emotional processing may continue as perceptual distortion subsides.
Residual mood elevation or introspective quality with mild perceptual sensitivity possible. Cognitive clarity gradually returns to baseline.
⚠ Avoid driving or operating machinery for at least 6 hours after the last noticeable effect.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Moderate
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 7 days
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- psilocin · psilo · LSD
Toxicity
No lethal dose data exist for 4-HO-EPT in any species — no animal studies, no dose-response curves, no therapeutic index estimates.safety citation needed
Postmortem Case
A 2024 study found unique 4-HO-EPT metabolites in a postmortem blood sample from a suspected intoxication case.[4] This is the only published fatality-adjacent report. Whether 4-HO-EPT caused the death has not been established — other substances may have been involved.
5-HT₂B Cardiac Concern
4-HO-EPT binds strongly to a receptor linked to heart valve damage when activated daily over months to years.[1] This is the same mechanism behind cardiac side effects from older daily-use drugs like fenfluramine. Whether intermittent psychedelic use carries any meaningful cardiac risk through this pathway is unknown — no heart monitoring data exist.
Cardiovascular Effects
Binding at histamine and adrenergic receptors suggests possible mild changes in heart rate and blood pressure.[1] Pupil dilation is consistently reported. No published cardiovascular monitoring data exist.
Psychological Risks
No substance-specific psychological adverse event data exist for 4-HO-EPT. The following risks are inferred from the serotonergic psychedelic class:
Acute psychological distress: anxiety and panic can occur, typically self-limiting but sometimes severe.[14]
Psychosis precipitation: People with a personal or family history of psychotic disorders face elevated risk of triggering a psychotic episode.[14]
Persistent visual disturbances (HPPD): Ongoing visual changes after use have been documented across this class of psychedelic.[15] No 4-HO-EPT-specific cases have been reported.
Tolerance and Dependence
4-HO-EPT is not habit-forming. A single dose triggers measurable tolerance within 24 hours — serotonin receptors reduce their sensitivity, making subsequent doses less effective.[5] Cross-tolerance extends to other serotonergic psychedelics. Community estimates place full tolerance reset at roughly 7 days.safety citation needed
No physical dependence or withdrawal has been documented for any classical serotonergic psychedelic. The rapid tolerance itself functions as a physiological deterrent to compulsive redosing.
Drug Interactions
The main risk of combining 4-HO-EPT with other substances is pushing serotonin activity to dangerous levels.
Tramadol: tramadol raises serotonin by blocking reuptake and stimulating release.[16] Combined with 4-HO-EPT, this creates a dangerous serotonin load. This interaction is classified as dangerous.
MAOIs: MAOIs block the enzyme expected to break down 4-HO-EPT, dramatically prolonging and intensifying the experience while creating serious risk of serotonin overload.[17] safety citation needed
SSRIs and SNRIs: Long-term use may blunt psychedelic effects through receptor adaptation, while theoretically raising serotonin syndrome risk at high doses.[17]
Cannabis: No data address this combination. Class-based observations suggest cannabis may intensify effects and increase anxiety risk.
Lithium: lithium combined with serotonergic psychedelics carries elevated seizure and cardiac risk. This combination is classified as dangerous.[14]
Contraindications
9 knownNo substance-specific contraindication data exist for 4-HO-EPT. The following are inferred from the serotonergic psychedelic classinferred:
Absolute contraindications:
- Personal or family history of psychotic disorders — serotonin receptor activation can trigger psychotic episodes
- Current lithium use — seizure and cardiac risk
- Current MAOI use — dangerous potentiation and serotonin overload risk
- Current tramadol use — serotonin toxicity risk
Relative contraindications:
- Bipolar disorder — risk of triggering a manic episode
- Cardiovascular disease — uncharacterized cardiovascular effects; 5-HT₂B affinity may pose additional concern for those with pre-existing valve conditions
- Pregnancy and breastfeeding — no safety data exist
- Current SSRI or SNRI use — bidirectional interaction risk
- Personal history of HPPD — risk of worsening
Harm Reduction[edit]
Forms & Identification
4-HO-EPT circulates as a powder, typically sold as the hemifumarate salt. As a 4-hydroxytryptamine, it degrades on exposure to air — discoloration or darkening of the powder may indicate breakdown. Reagent testing can help distinguish it from other tryptamines but cannot confirm identity or purity; definitive identification requires laboratory analysis.
It is active in the milligram range, and small dose differences produce meaningfully different experiences. Accurate milligram-scale weighing (±2 mg) is essential — eyeballing or volumetric estimation is unsafe for any substance in this potency range.
Guidelines
- Test substance identity with an appropriate reagent kit before use
- Weigh doses with a milligram-precision scale — never estimate
- Start with a low dose to assess individual sensitivity, especially given the absence of controlled dose-finding data
- Allow at least 60 minutes before considering the onset incomplete — redosing before full effects manifest is a common cause of unexpectedly intense experiences
- Eat lightly several hours before; avoid heavy meals
- Keep the environment simple, safe, and controllable — minimize access to heights, traffic, and bodies of water
- Have a sober, trusted person present
- Maintain adequate hydration throughout the experience
Set & Setting
The psychological context of use strongly shapes the experience. A calm, familiar environment with trusted company significantly reduces the risk of a difficult experience. Being anxious, sleep-deprived, or emotionally unstable raises that risk.
A sober sitter — someone who remains unimpaired and is experienced with psychedelic states — is strongly recommended, especially for first experiences or higher doses.
Aftercare & integration. The days following a psychedelic experience often involve continued emotional processing. Journaling or talking through the experience with a trusted person can help consolidate insights. Sleep and appetite disruption on the day of use are normal and typically resolve within 24 hours.
If unusual visual disturbances, persistent anxiety, or mood changes last beyond a few days, professional support is advisable. Integration-focused therapists familiar with psychedelic experiences can help with difficult or confusing material.
Recovery & Support
4-HO-EPT is not considered addictive, and compulsive use is rare among classical psychedelics. Psychological reliance — using psychedelic experiences to avoid rather than address underlying difficulties — can develop with any substance in this class.
If use is becoming a coping mechanism rather than an intentional practice, harm reduction organizations and psychedelic peer support services can provide guidance.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Most difficult psychedelic experiences are uncomfortable but not medically dangerous. Seek immediate help if any of the following occur: self-harm behavior or expressed intent, complete disconnection from reality with inability to recognize surroundings or people, seizures, loss of consciousness, or chest pain.
Immediate steps:
- 1. Move the person to a quiet, low-stimulation environment
- 2. Speak calmly and reassuringly — do not argue with or restrain them unless there is immediate danger of self-harm
- 3. If unconscious, place in the recovery position (on their side, airway clear)
- 4. Call emergency services if symptoms escalate or the person becomes unresponsive
- 5. Do not induce vomiting
What to tell the dispatcher: State what was taken, how much, when, and current symptoms. Good Samaritan laws in many jurisdictions protect callers from prosecution for drug-related offenses when seeking emergency help.
Legal Status[edit]
As of May 2026, 4-HO-EPT is not specifically scheduled in most jurisdictions, though structural analog provisions and blanket novel psychoactive substance laws may apply.[18] citation needed
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not specifically scheduled | Not listed under the Controlled Substances Act. The Federal Analogue Act (21 U.S.C. § 813) may apply if intended for human consumption, as 4-HO-EPT is a structural analog of psilocin (Schedule I). |
| United Kingdom | Class A (illegal) | Controlled under the Misuse of Drugs Act 1971 via the tryptamine catch-all clause, which captures substituted tryptamines regardless of individual scheduling. |
| Germany | Controlled (NpSG) | Covered by the Neue-psychoaktive-Stoffe-Gesetz (NpSG) since July 18, 2019, which provides blanket control of novel psychoactive substances by structural class. |
| Canada | Not specifically controlled | Not listed under the Controlled Drugs and Substances Act (CDSA). Analogue provisions may apply depending on prosecutorial interpretation. |
| Australia | Not specifically scheduled | Not individually listed under the SUSMP. Analogue or suspicious substance provisions may apply under state and territory legislation. |
| Switzerland | Not controlled | Not listed under the Betäubungsmittelgesetz. No blanket NPS legislation applies. |
Legal status changes frequently and varies by jurisdiction. This information is not legal advice — verify current local regulations before acting.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Moderate
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 7 days
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- psilocin · psilo · LSD
Toxicity
No LD₅₀ data have been published for 4-HO-EPT in any species. No animal toxicology studies, dose-response lethality curves, or therapeutic index estimates exist. The acute toxic dose in humans is unknown.safety citation needed
Postmortem Case
A 2024 study identified unique 4-HO-EPT metabolites in a human postmortem blood sample from a case of suspected intoxication.[4] This is the only published fatality-associated case. The causal relationship between 4-HO-EPT and death has not been established; polydrug involvement cannot be excluded. This case should not be interpreted as establishing lethality for 4-HO-EPT alone.
5-HT₂B Cardiac Concern
4-HO-EPT binds strongly to the serotonin₂B receptor.[1] Chronic activation of this receptor is an established cause of heart valve damage, as demonstrated for fenfluramine and certain ergot derivatives prescribed for daily use over months to years. Whether intermittent psychedelic use — with tolerance-enforced spacing — carries meaningful cardiac risk is unknown. No heart monitoring data exist for 4-HO-EPT users.
Cardiovascular Effects
Binding at histamine H₁ and adrenergic α₂A receptors suggests potential for mild changes in heart rate and blood pressure.[1] Pupil dilation is consistently reported. No published cardiovascular monitoring data exist.
Psychological Risks
No substance-specific psychological adverse event data have been published for 4-HO-EPT. The following risks are inferred from the serotonergic psychedelic class:
Acute psychological distress: anxiety, panic, and deeply unpleasant experiences occur with serotonergic psychedelics at rates influenced by dose, set, and setting. These episodes are typically self-limiting but can be severe.[14]
Psychosis precipitation: Serotonergic psychedelics can trigger psychotic episodes in individuals with personal or family history of psychotic disorders.[14]
Hallucinogen persisting perception disorder (HPPD): Persistent visual disturbances following serotonin 2A receptor agonist use have been documented across the class.[15] No 4-HO-EPT-specific HPPD cases have been reported.
Tolerance and Dependence
4-HO-EPT is not considered habit-forming. Classical serotonergic psychedelics consistently demonstrate low abuse liability due to rapid tolerance development and absence of meaningful mesolimbic pathway activation.
Tolerance develops rapidly — a single dose induces measurable tolerance within 24 hours through 5-HT₂A downregulation.[5] Cross-tolerance extends to other 5-HT₂A agonist psychedelics. Community estimates place tolerance half-life at approximately 3 days and full reset at approximately 7 days.safety citation needed
No physical dependence or withdrawal has been documented for any classical serotonergic psychedelic. The rapid tolerance itself functions as a physiological deterrent to compulsive redosing.
Drug Interactions
The primary risk of combining 4-HO-EPT with other serotonergic agents is serotonin syndrome. As a multi-target serotonin receptor agonist, 4-HO-EPT adds serotonergic load to any co-administered drug that increases synaptic serotonin.
Tramadol: tramadol inhibits serotonin reuptake and stimulates serotonin release.[16] Combination with 4-HO-EPT produces reinforced serotonergic load with clinically significant serotonin toxicity risk. This interaction is classified as dangerous.
MAOIs: Monoamine oxidase inhibitors block the inferred primary metabolic pathway for 4-HO-EPT. Co-administration would be expected to dramatically prolong and intensify the experience while creating serious serotonin syndrome risk.[17] safety citation needed
SSRIs and SNRIs: Serotonergic antidepressants produce bidirectional interactions: chronic use may blunt psychedelic effects through receptor downregulation, while theoretical serotonin toxicity risk exists at high doses.[17]
Cannabis: No published data address this combination. Class-based observations suggest cannabis may intensify subjective effects and increase anxiety risk.
Lithium: lithium is considered dangerous in combination with serotonergic psychedelics due to increased seizure risk and potential cardiac effects.[14]
Contraindications
9 knownNo substance-specific contraindication data exist for 4-HO-EPT. The following are inferred from the serotonergic psychedelic classinferred:
Absolute contraindications:
- Personal or family history of psychotic disorders — 5-HT₂A agonism can precipitate psychotic episodes
- Current lithium use — seizure and cardiac risk
- Current MAOI use — serotonin syndrome risk and uncontrolled potentiation
- Current tramadol use — serotonin toxicity risk
Relative contraindications:
- Bipolar disorder — risk of manic episode precipitation
- Cardiovascular disease — uncharacterized cardiovascular effects; 5-HT₂B affinity may pose additional concern for individuals with pre-existing valve conditions
- Pregnancy and breastfeeding — no reproductive or developmental safety data exist
- Current SSRI or SNRI use — bidirectional interaction risk
- Personal history of HPPD — theoretical risk of worsening
Harm Reduction[edit]
Forms & Identification
4-HO-EPT circulates primarily as a research chemical powder, typically sold as the hemifumarate salt. As a 4-hydroxytryptamine, it is susceptible to oxidative degradation — discoloration or darkening of the powder may indicate breakdown. Reagent testing can help distinguish it from other tryptamines but cannot confirm identity or purity with certainty; definitive identification requires laboratory analysis.
The compound is active in the milligram range with meaningful dose-response differences across the span. Accurate milligram-scale weighing (±2 mg) is essential — volumetric estimation or eyeballing is unsafe for any substance in this potency range.
Guidelines
- Test substance identity with an appropriate reagent kit before use
- Weigh doses with a milligram-precision scale — never estimate
- Start with a low dose to assess individual sensitivity, especially given the absence of controlled dose-finding data
- Allow at least 60 minutes before considering the onset incomplete — redosing before full effects manifest is a common cause of unexpectedly intense experiences
- Eat lightly several hours before; avoid heavy meals
- Keep the environment simple, safe, and controllable — minimize access to heights, traffic, and bodies of water
- Have a sober, trusted person present
- Maintain adequate hydration throughout the experience
Set & Setting
As with all serotonergic psychedelics, the psychological context of use strongly shapes the experience. A calm, familiar environment with trusted company significantly reduces the risk of acute distress. Individuals who are anxious, sleep-deprived, or in an unstable emotional state face elevated risk of difficult experiences.
A sober sitter — someone experienced with psychedelic states who remains unimpaired throughout — is strongly recommended, particularly for first experiences or higher doses.
Aftercare & integration. The days following a psychedelic experience often involve continued emotional processing. Journaling or talking through the experience with a trusted person can help consolidate insights and process difficult material. Sleep and appetite disruption on the day of use are normal and typically resolve within 24 hours.
If unusual perceptual disturbances, persistent anxiety, or mood changes last beyond a few days, professional support is advisable. Integration-focused therapists familiar with psychedelic experiences can provide structured processing for difficult or confusing material.
Recovery & Support
4-HO-EPT is not considered addictive, and compulsive use patterns are rare among classical psychedelics. However, psychological reliance on psychedelic experiences — using them to avoid rather than address underlying difficulties — can develop with any substance in this class.
If psychedelic use is becoming a coping mechanism rather than an intentional practice, harm reduction organizations and psychedelic peer support services can provide guidance.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Most difficult psychedelic experiences are uncomfortable but not medically dangerous. Seek immediate help if any of the following occur: self-harm behavior or expressed intent, complete disconnection from reality with inability to recognize surroundings or people, seizures, loss of consciousness, or chest pain.
Immediate steps:
- 1. Move the person to a quiet, low-stimulation environment
- 2. Speak calmly and reassuringly — do not argue with or restrain them unless there is immediate danger of self-harm
- 3. If unconscious, place in the recovery position (on their side, airway clear)
- 4. Call emergency services if symptoms escalate or the person becomes unresponsive
- 5. Do not induce vomiting
What to tell the dispatcher: State what was taken, how much, when, and current symptoms. Good Samaritan laws in many jurisdictions protect callers from prosecution for drug-related offenses when seeking emergency help.
Legal Status[edit]
As of May 2026, 4-HO-EPT is not specifically scheduled in most jurisdictions. Its legal status is primarily determined by structural analog provisions and blanket novel psychoactive substance legislation. All jurisdiction-specific information below is derived from web sources and has not been verified against official regulatory databases.[18] citation needed
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not specifically scheduled | Not listed under the Controlled Substances Act. The Federal Analogue Act (21 U.S.C. § 813) may apply if intended for human consumption, as 4-HO-EPT is a structural analog of psilocin (Schedule I). |
| United Kingdom | Class A (illegal) | Controlled under the Misuse of Drugs Act 1971 via the tryptamine catch-all clause, which captures substituted tryptamines regardless of individual scheduling. |
| Germany | Controlled (NpSG) | Covered by the Neue-psychoaktive-Stoffe-Gesetz (NpSG) since July 18, 2019, which provides blanket control of novel psychoactive substances by structural class. |
| Canada | Not specifically controlled | Not listed under the Controlled Drugs and Substances Act (CDSA). Analogue provisions may apply depending on prosecutorial interpretation. |
| Australia | Not specifically scheduled | Not individually listed under the SUSMP. Analogue or suspicious substance provisions may apply under state and territory legislation. |
| Switzerland | Not controlled | Not listed under the Betäubungsmittelgesetz. No blanket NPS legislation applies. |
The structural relationship to psilocin — controlled internationally under the 1971 United Nations Convention on Psychotropic Substances — means that analog law provisions may apply in jurisdictions with such legislation, even where 4-HO-EPT is not individually named. The United Kingdom's tryptamine catch-all provision represents the most unambiguous control, classifying all substituted tryptamines as Class A regardless of specific enumeration.
Frequently asked questions
What is 4-HO-EPT?
4-HO-EPT is a synthetic substituted tryptamine psychedelic with an asymmetric N-ethyl-N-propyl substitution on the 4-hydroxytryptamine scaffold. It acts as a multi-target serotonin receptor agonist, with highest affinity at 5-HT₂B (Ki = 62 nM) and confirmed hallucinogenic potential via 5-HT₂A agonism.
How long does 4-HO-EPT last?
Total duration by route of administration — Oral: 3 – 7 hours. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.
Where can I find dosage information for 4-HO-EPT?
Psychedex publishes a dosage table for 4-HO-EPT on this page covering these routes of administration: oral. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with 4-HO-EPT?
The highest-severity documented interactions for 4-HO-EPT: MAOIs (Lethal), Dopamine agonists (Dangerous), GHB, Baclofen (Dangerous), GHB, GBL (Dangerous), Ibogaine (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is 4-HO-EPT addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for 4-HO-EPT: tolerance builds rapid; full reset takes 7 days; cross-tolerance develops with psilocin, psilocybin, LSD, DMT, mescaline, DOI. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1]
- [2]
- [3]
- [4]
- [5] ^abde la Fuente Revenga M, Jaster AM, McGinn J, Silva G, Saha S, Gonzalez-Maeso J (2022) Tolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT2A Receptor Agonists in Mice — ACS Chemical Neuroscience doi:10.1021/acschemneuro.2c00170
- [6]
references
- [1]
- [2]
- [3]
- [4]
- [5] ^abde la Fuente Revenga M, Jaster AM, McGinn J, Silva G, Saha S, Gonzalez-Maeso J (2022) Tolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT2A Receptor Agonists in Mice — ACS Chemical Neuroscience doi:10.1021/acschemneuro.2c00170
- [6]